Glomerular prostanoid production is modified by plasma samples of hypertensive and diabetic patients

Acta Physiologica Hungarica

Volumn 85, Issue 1, 1998, Pages 17-28

  Szekacs B ^a   Vajo Z ^b   Juhasz I ^a   Vaslaki, L ^c   Nagy, V ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b MARICOPA MEDICAL CENTER   (United States)

^c Erzsebet Hospital   (Hungary)

Author keywords

Diabetes mellitus; Hypertension; Isolated glomeruli; Kidney; NIDDM; Plasma; Prostacyclin; Thromboxane

Indexed keywords

EID: 1542678869     PISSN: 0231424X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Mackenzie, H. S., Lawler, E. V., Brenner, B. M.: Congenital oligonephropathy: The fetal law in essential hypertension? Kidney Int., 49 (suppl. 55), S30-S34.
2. Brazy, P. C., Stead, W. W., Fritzwilliam, J. F.: Progression of renal insufficiency: Role of blood pressure. Kidney Int., 35, 670-674 (1989).
3. Rostand, S. G., Brown, G., Kirk, K. A, Rutsky, E. A, Dustan, H. P.: Renal insufficiency in treated essential hypertension. N. Engl. J. Med., 320, 684-688 (1989).
4. Krolewski, A. S., Canessa, M., Warram, I. H., Laffel, L. M., Christlieb, A. R., Knowler, W. C. et al.: Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N. Engl. J. Med., 318, 140-145 (1988).
5. Wang, S. L., Head, J., Stevens, L., Fulelr, J. H.: Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Diabetes Care, 19, 305-312 (1996).
6. Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M. et al.: Hyperinsulinemia: a link between hypertension obesity and glucose intolerance. J. Clin. Invest., 75, 809-817 (1985).
7. Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M. A., Oleggini, M., Graziadei, I. et al.: Insulin resistance in essential hypertension. N. Engl. J. Med., 317, 350-357 (1987).
8. Reaven, G. M.: Insulin resistance hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am. J. Med., 90 (suppl. 2A), S7-S12.
9. Kirschenbaum, M. A., Seros, E. R.: Effect of prostaglandin inhibition on glomerular filtration rate in normal and uremic rabbits. Prostaglandins, 22, 245-254 (1981).
10. Barcello, U. O., Weiss M., Pollak, V. E.: Effects of dietary prostaglandin precursor on progression of experimentally induced chronic renal failure. J. Lab. Clin. Med., 100, 786-797 (1982).
11. Patrono, C., Ciabattoni, G., Remuzzi, G., Gotti, E., Bombardien, S. T. et al.: The functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythrematosis. J. Clin. Invest., 76, 1011-1018 (1985).
12. Purkerson, M. L., Joist, J. H., Yates, J., Valdes, A., Morrison, A., Klahr, S.: Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc. Natl. Acad. Sci. USA, 82, 193-197 (1985).
13. Matsuo, Y., Takagawa, I., Koshida, H.: Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murin lupus nephritis. Pharmacology, 50, 1-8 (1995).
14. Milot, A., Lambert, R., Lebel, M., Cusson, J. R., Larochelle, P.: Prostaglandins and renal function in hypertensive patients with unilateral renal stenossis and patients with essential hypertension. J. Hypertension, 14, 765-771 (1996).
15. Stahl, R. A., Kudelka, S., Paravicini, M., Schollmeyer, P.: Prostaglandin and thromboxane formation in glomeruli from rats with reduced renal mass. Nephron, 42, 252-257 (1986).
16. Folkert, V. W., Sclondorff: Altered prostaglandin synthesis by glomeruli from rats with unilateral ureter ligation. Am. J. Physiol., 241 (RFEPh. 10), F289-F29 (1981).
17. Folkert, v. W., Schlondorf, D.: Prostanoid synthesis in isolated glomeruli. Prostaglandins, 17, 79-86 (1979).
18. Farman, N., Pradelles, P., Bonvalet, J. P.: PGE2, PGF2alfa, 6-keto-PGF 1 alfa and TxB2 synthesis along the rabbit nephron. Am. J. Physiol. (RFEP 21), F53-F59 (1987).
19. Grose, J. H., Lebel, M., Gbeassor, F. M.: Diminished urinary prostacyclin metabolite in essential hypertension. Clin. Sci., (suppl.) 59, s121-s123 (1980).
20. Hornych, A., Safar, M., Bariety, J. et al.: Thromboxane B2 in borderline and essential hypertensive patients. Prostaglandins Leukotrienes Med., 10, 145-155 (1983).
21. Antonipilali, I. Nadler, J., Vu E. J., Bughi, S. et al.: A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J. Clin. Endocrin. Metab., 81, 1940-1945 (1996).
22. Umeda, F., Kuroki, T., Nawata, H.: Prostaglandins and diabetic nephropathy. J. Diabetes-Complications, 9, 334-336 (1995).
23. Tajiri, Y., Inoguchi, T., Umeda, F., Nawata, H.: Reduction of urinary albumin excretion by thromboxane synthesis inhibitor OKY-046, through modulating renal prostaglandins inpatiems with diabetic nephropathy. Diabetes Res. Clin. Pract., 10, 231-237 (1990).
24. Székâcs, B., Juhász, I.: Examination of vasopressor responsiveness potentiating plasma factor in hypertensive patients. Cor et Vasa, 22, 104-109 (1980).
25. Bachman, J., Schlüter, H., Storkebaum, W., Witzel, H., Zidek, W.: Effect of plasma from essential hypertensives on vascular tone of aortic strips, isolated perfused mesentery and isolated perfused kidney. Life Sci., 47, 1365-1374 (1990).
26. Ouchi, Y., Han, S. Z., Kim, S., Akishita, M., Kozaki, K. et al.: Augmented contractile function and abnormal Ca2+ handling in the aorta of Zucker obese rats with insulin resistance. Diabetes, 45 (suppl. 3), 855-858 (1996).
27. Kamata, K., Sugiura, M., Kasuya, Y.: Decreased Ca2+ influx into the endothelium contributes to the decrease in endothelium-dependent relaxation in aorta of streptozotocin-induced diabetic mice. Res. Commun. Mol. Pathol. Pharmacol., 90, 69-74 (1995).
28. Donellys, M.: Accumulation of glycated albumin in end-stage renal failure: evidence for the principle of "physiological albuminuria". Am. J. Kidney Dis., 28, 62-66 (1996).
29. Holler, C., Auinger, M., Ulberth, F., Irsigler, K.: Eicosanoid precursors: potencial factors for atherogenesis in diabetic CAP patients? Perit. Dial. Int., 16 (suppl. 1), S250-S253 (1996).
30. Hegele, R. A.: The pathogenesis of atherosclerosis Clin. Chim. Acta., 246 (1-2), 21-38 (1996).
31. Ferri, C., Bellini, C., Desideri, G., De Mattia, G., Santucci, A.: Endogenous insulin modulates circulating endothelin-1 concentrations in humans. Diabetes Care, 19, 504-506 (1996).
32. Kupcova, V., Turecky, L., Carsky, P., Kolesár, P., Brixová, E.: Lipid peroxidation products in the sera of diabetic patients. In: Fehér, J., Blázovics, A., Matkovics, B., Mézes, M. eds: Role of free radicals in biological systems. Akadémiai Kiadó Budapest, 1993.
33. Sraer, J., Sraer, J. D., Chansel, D., Russo-Marie, F., Kouznetzova, B., Ardaillou, R.: Prostaglandin synthesis by isolated glomeruli. Molecular and Cellular Endocrinology, 16, 29-37 (1980).
34. Wu, K. K., Thiagarajan, P.: Role of endothelium in thrombosis and hemostasis. Annu. Rev. Med., 47, 315-331 (1996).
35. Egemen, N., Baskaya, M. K., Turker, R. K., Unlu, A., Caglar, S. et al.: Protection by Iloprost (stable analogue of prostacyclin) of endothelial damage due to chronic vasospasm in dogs: an elctronmicroscope study. Neurol. Res., 17, 301-306 (1995).
36. Mashima, S., Shirakami, G., Mitsuyoshi, A., Nakagami, M., Morimoto, T. et al.: Evaluation of the protective effect of a novel prostacyclin analog on mesenteric circulation following warm ischemia. Eur. Surg. Res., 28, 14-25 (1996).
37. Zaugg, C. E., Hornstein, P. S., Zhu P., Simper, D., Luscher, T. F. et al.: Endothelin-1 induced release of thromboxane A2 increases the vasoconstrictor effect of endothelin-1 in postischemic reperfused rat hearts. Circulation, 94, 742-747 (1996).
38. Fuse, I., Ootsuka, T., Hattori, A., Mito, M., Shibata, A.: Vascular thromboxane formation in hemostasis mechanism: correlation between bleeding time and vascular TxB2 in a patient with congenital platelet cyclo-oxygenase insufficiency. Int. J. Hematol., 63, 317-324 (1996).
39. Herrick, A. L., Illingworth, K., Blann, A., Hay, C. R., Holis, S. et al.: Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann. Rheum. Dis., 55, 122-127 (1996).
40. Cervar, M., Kainer, F., Jones, C. J., Desoye, G.: Altered release of endothelin-1,2 and thromboxane B2 from throphoblastic cells in pre-eclampsia. Eur. J. Clin. Invest., 26, 30-37 (1996).
41. Patrono, C., Ciabattoni, G., Patrignani, P., Filabozzi, P., Pinca, E. et al.: Evidence for a renal origin of urinary thromboxane B2 in health and disease. Adv. Prostagl. Thromb. Leukotr. Res., 11, 493-498 (1983).
42. Frochlich, J. C., Wilson, T. W., Sweetman, B. J., Smiegel, M., Nies, A. S. et al.: Urinary prostaglandins: identification and origin. J. Clin. Invest., 55, 763-770 (1975).
43. Sun, F. F., Taylor, B. M., McGuire, J. C., Wong, P. Y., Malik, K. U. McGiff, J. C.: Metabolic disposition of prostacyclin. In: Prostacyclin, eds Vane, J. R., Gregstrom, L., Raven Press, N.Y., 1979, pp. 119-131.
44. Székâcs, B., Mohácsi, E., Gachályi, B., Tihanyi, K., Juhász, I., Horváth, B.: Renal thromboxane response to blood pressure fall in essential hypertension: examination of a possible relationship with other urinary prostanoids and plasma renin activity. IRCS Med. Sci., 14, 53-54 (1986).
45. Székács, B., Juhász, I., Gachályi, B., Fehér, J.: TxA2-PGI2-PGF2alfa responses in the kidney to blood pressure reduction induced by vasodilator/vasorelaxing agents with different action in patients with essential hypertension. Acta Physiol. Hung., 81, 403-416 (1993).
46. Székács, B., Nádasy, G., Vajó, Z., Juhász, I., Fehér, J., Monos, E.: Prostacyclin and thromboxane production of rat and cat arterial tissue is altered independently by several vasoactive substances. Prostaglandins, 52, 221-239 (1996).
47. Mohácsi, E., Székács, B., Gachályi, B., Tihanyi, K., Juhász, I.: Thromboxan A2 és prosztaciklin metabolitok uritésének vizsgálata esszenciális hypertoniás betegek vizeletében. Urol. Nephrol. Szle., 13, 109-113 (1986).
48. Nishimura, M., Nozaki, O., Nakano, H., Tsuchida, H., Yamada, K.: The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM. J. Diabetes Complications, 9, 330-333 (1995).
49. Mehta, J., Mehta, P., Ostrowski, N., Brigmon, L.: Ca33 blocker diltiazem inhibits human platelet TxA2 synthesis and increases vesse wall PGI2 release (abstr.). Clin. Res., 31, 25, 1A (1983).
50. Umeda, F., Ono, Y., Masakado, M., Sekiguchi, N., Yamauchi, T. et al.: Prostacyclin-stimulating factor, novel protein, and diabetic angiopathy. Diabetes, 45 (suppl. 3), S111-S113 (1996).
51. Chatzipanteli, K., Head, C., Megerman, J., Axelrod, L.: The relationship between plasma insulin level, prostaglandin production by adipose tissue, and blood pressure in normal rats and rats with diabetes mellitus and ketoacidosis. Metabolism, 45, 691-698 (1996).
52. Yokoyoma, H., Myrup, B., Rossing, P., Ostergaard, P. B.: Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabetes Care, 19, 441-445 (1996).